Boston Scientific Corporation has received approval from the US FDA for the Vercise deep brain stimulation (DBS) system to treat the symptoms of Parkinson’s disease (PD). DBS works by stimulating a targeted region of the brain through implanted leads that are powered by a device called an implantable pulse generator (IPG).
The Vercise IPG is the smallest, rechargeable DBS device available in the United States and, depending on individual use, can have a battery life of more than 15 years. The Vercise system has a proprietary capability that independently controls the amount of current delivered by each of the electrodes on the implanted leads. The system leads have eight contacts with a long total span of 15.5 mm, tight spacing between each contact of 0.5 mm, and multilumen construction. These system features are designed to work together to address common challenges in DBS therapy such as fluctuations in symptoms and the progressive nature of the condition by offering more adaptable delivery of stimulation.
Since 2012, Boston Scientific has continued to advance its DBS portfolio, including the launch this year in Europe of the Vercise Gevia deep brain stimulation system with the Cartesia Lead, providing the first directional, rechargeable, and magnetic resonance (MR) conditional system. The company also recently introduced new programming software, Neural Navigator 2, which enables physicians to visualize the stimulation field while configuring DBS programs for patients. The company is also supporting ongoing research in the field, including the use of DBS for stroke recovery and to treat Alzheimer’s disease.